Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

MyoKardia (NASDAQ:MYOK) Now Covered by Analysts at JPMorgan. The Target Price is $54.0

JP Morgan Analyst Rating Change MyoKardia NASDAQ:MYOK

MyoKardia (NASDAQ:MYOK) Price Target & New Coverage by JPMorgan

JPMorgan issued “Overweight” rating on Myokardia (NASDAQ:MYOK). The firm began coverage on shares of MYOK in an analyst report revealed to clients on Tuesday morning. JPMorgan’s target price indicates upside of 40.44 % from the company’s stock close price.

After the coverage NASDAQ:MYOK is at the moment trading -0.94% lower at $36.85 as of 10:03 AM New York time. MyoKardia’s stock is 0% in the past 200 days. It has underperformed the S&P500, which has surged 6.00% in the same time.

MyoKardia (NASDAQ:MYOK) Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

MyoKardia (NASDAQ:MYOK) traded down -0.94% on 12 December, hitting $36.85. A total of 265,178 shares of the company’s stock traded hands. This is down from average of 334,648 shares. MyoKardia has a 52 week low of $10.55 and a 52 week high of $49.55. The company has a market cap of $1.32B and a P/E ratio of 0.

Get the latest MyoKardia (NASDAQ:MYOK) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post MyoKardia (NASDAQ:MYOK) Now Covered by Analysts at JPMorgan. The Target Price is $54.0 appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

MyoKardia (NASDAQ:MYOK) Now Covered by Analysts at JPMorgan. The Target Price is $54.0

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×